CRLF2 and acute lymphoblastic leukemia: Accordingly, administration of the TSLPRα blocking antibody 1E10 has been shown to inhibit both TSLP-triggered cell proliferation and STAT transcription factor activation [15], and TSLPR chimeric antigen receptor T-cell (CAR-T) therapy has been shown to eradicate human CRLF2-overexpressing ALL in xenograft models [16].